Table 1—

Mean pharmacodynamic summary measures of 6 mg INH, subcutaneous injection of 18 U RHI, and subcutaneous injection of 18 U ILP on three different study days in 17 healthy volunteers (baseline values subtracted)

Serum glucose measuresINH (A)ILP (B)RHI (C)Ratio/difference90% CIP values*
Time to early half-maximal effect324148−17 (A−C)−24 to −10<0.001
(tGIRearly 50%) (min)−10 (A−B)−17 to −3<0.05
−7 (B−C)−14 to 0NS
Maximal metabolic effect (GIRmax)8.711.29.889% (A/C)79–101NS
(mg · kg–1 · min−1)78% (A/B)69–88<0.01
115% (B/C)101–130NS
Time to maximal effect (tGIRmax)143137193−49 (A−C)−77 to −21<0.01
(min) 7 (A−B)−22 to 35NS
−56 (B−C)−84 to −28<0.01
Time to late half-maximal effect387313415−29 (A−C)−71 to 13NS
(tGIRlate 50%) (min)74 (A−B)32–116<0.01
−103 (B−C)−145 to −61<0.001
AUC-GIR0–60 (g/kg)0.230.240.17134% (A/C)107–168<0.05
96% (A/B)76–120NS
140% (B/C)112–176<0.05
AUC-GIR0–180 (g/kg)1.211.451.17103% (A/C)90–119NS
84% (A/B)73–96<0.05
124% (B/C)108–142<0.05
AUC-GIR0–600 (g/kg)3.033.163.4488% (A/C)77–101NS
96% (A/B)84–110NS
92% (B/C)80–105NS
  • *

    * One-sided for tGIRmax and AUC-GIR0–60; two-sided for all other measures;

  • arithmetic mean;

  • geometric mean.